Qube Research & Technologies Ltd Buys New Shares in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Qube Research & Technologies Ltd bought a new stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 26,937 shares of the company’s stock, valued at approximately $2,615,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Capital International Investors increased its position in shares of Biohaven Pharmaceutical by 4.6% in the 1st quarter. Capital International Investors now owns 5,578,232 shares of the company’s stock valued at $381,272,000 after acquiring an additional 247,254 shares during the period. BlackRock Inc. increased its position in shares of Biohaven Pharmaceutical by 24.0% in the 2nd quarter. BlackRock Inc. now owns 4,691,578 shares of the company’s stock valued at $455,460,000 after acquiring an additional 908,024 shares during the period. Stifel Financial Corp increased its position in shares of Biohaven Pharmaceutical by 0.9% in the 1st quarter. Stifel Financial Corp now owns 2,564,822 shares of the company’s stock valued at $175,306,000 after acquiring an additional 22,348 shares during the period. Vanguard Group Inc. increased its position in shares of Biohaven Pharmaceutical by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,321,270 shares of the company’s stock valued at $128,268,000 after acquiring an additional 48,374 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Biohaven Pharmaceutical by 3.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,231,728 shares of the company’s stock valued at $119,576,000 after acquiring an additional 44,535 shares during the period. 92.14% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Biohaven Pharmaceutical stock opened at $136.29 on Thursday. Biohaven Pharmaceutical Holding Company Ltd. has a twelve month low of $62.57 and a twelve month high of $151.51. The firm’s 50-day moving average price is $130.61 and its 200 day moving average price is $104.59.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Sunday, August 8th. The company reported ($3.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.77) by ($0.46). The company had revenue of $92.93 million during the quarter, compared to the consensus estimate of $85.85 million. During the same quarter last year, the firm posted ($2.55) EPS. The company’s revenue was up 858.3% compared to the same quarter last year. Sell-side analysts forecast that Biohaven Pharmaceutical Holding Company Ltd. will post -11.73 EPS for the current year.

Several equities analysts recently issued reports on BHVN shares. HC Wainwright reissued a “buy” rating and issued a $160.00 target price (up from $135.00) on shares of Biohaven Pharmaceutical in a research report on Wednesday, October 6th. The Goldman Sachs Group increased their price target on Biohaven Pharmaceutical from $151.00 to $170.00 and gave the stock a “buy” rating in a research report on Wednesday, October 6th. UBS Group downgraded Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating and increased their price target for the stock from $108.00 to $109.00 in a research report on Tuesday, August 10th. Cantor Fitzgerald increased their price target on Biohaven Pharmaceutical from $151.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, September 13th. Finally, Cowen increased their price target on Biohaven Pharmaceutical from $90.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Biohaven Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $137.45.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators.

Read More: Fibonacci Channel

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.